|
|
News Breaks | | | | November 13, 2012 | | 08:33 EDT |  | IDRA | Idera Pharmaceuticals initiates dosing in Phase 1 trial of IMO-8400
Idera Pharmaceuticals announced the initiation of dosing in a Phase 1 trial of IMO-8400. IMO-8400 is an antagonist of Toll-like receptors, or TLRs, 7, 8 and 9, and is the second clinical candidate in Idera's autoimmune disease program. Idera expects to develop IMO-8400 for the treatment of lupus as an initial indication. Idera also announced the presentation of preclinical data on IMO-8400 at the American College of Rheumatology that support its potential to treat autoimmune diseases through inhibition of Th1, Th17, and inflammasome activation | |
|
News For IDRA From The Last 14 Days Check below for free stories on IDRA the last two weeks. |
|
|
| May 15, 2013 | | 08:20 EDT |  | IDRA | Idera Pharmaceuticals reports Q1 EPS (15c), one estimate (19c)
 Subscribe for More Information | | | May 8, 2013 | | 07:18 EDT | | IDRA | Idera Pharmaceuticals' IMO-3100 for psoriasis shows positive Phase 2 results
Subscribe for More Information | |
|
|
|
|
|
|
